Trial Profile
CDK4/6 Inhibition in Locally Advanced/Metastatic Chordoma (NCT-PMO-1601)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Dec 2023
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary)
- Indications Chordoma
- Focus Proof of concept; Therapeutic Use
- Acronyms NCT-PMO-1601
- 24 Mar 2023 Status changed from recruiting to completed.
- 24 Mar 2023 Status changed from recruiting to completed.
- 13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress